000155385 001__ 155385
000155385 005__ 20240611120547.0
000155385 0247_ $$2doi$$a10.1002/mds.28624
000155385 0247_ $$2pmid$$apmid:33951244
000155385 0247_ $$2ISSN$$a0885-3185
000155385 0247_ $$2ISSN$$a1531-8257
000155385 0247_ $$2altmetric$$aaltmetric:105350439
000155385 037__ $$aDZNE-2021-00625
000155385 041__ $$aEnglish
000155385 082__ $$a610
000155385 1001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b0$$eFirst author
000155385 245__ $$aCortical [18 F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes.
000155385 260__ $$aNew York, NY$$bWiley$$c2021
000155385 3367_ $$2DRIVER$$aarticle
000155385 3367_ $$2DataCite$$aOutput Types/Journal article
000155385 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718025011_5320
000155385 3367_ $$2BibTeX$$aARTICLE
000155385 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155385 3367_ $$00$$2EndNote$$aJournal Article
000155385 520__ $$aCorticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (~50% of cases) or mixed 3-repeat/4-repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases).The aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [18 F]PI-2620 in patients with corticobasal syndrome.Forty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [18 F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [18 F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [18 F]PI-2620 binding was correlated with clinical and demographic data.Twenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [18 F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [18 F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [18 F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [18 F]PI-2620 signal reflected contralateral predominance of clinical disease severity.Our data indicate a value of [18 F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [18 F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000155385 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155385 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000155385 588__ $$aDataset connected to DataCite
000155385 650_7 $$2Other$$aAlzheimer's disease
000155385 650_7 $$2Other$$aPET
000155385 650_7 $$2Other$$acorticobasal syndrome
000155385 650_7 $$2Other$$afour-repeat tauopathies
000155385 650_7 $$2Other$$atau
000155385 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000155385 650_2 $$2MeSH$$aAmyloid beta-Peptides
000155385 650_2 $$2MeSH$$aDiagnosis, Differential
000155385 650_2 $$2MeSH$$aHumans
000155385 650_2 $$2MeSH$$aPositron-Emission Tomography
000155385 650_2 $$2MeSH$$aSyndrome
000155385 7001_ $$0P:(DE-HGF)0$$aBrendel, Matthias$$b1
000155385 7001_ $$0P:(DE-HGF)0$$aFinze, Anika$$b2
000155385 7001_ $$0P:(DE-2719)9000882$$aWeidinger, Endy$$b3
000155385 7001_ $$aBötzel, Kai$$b4
000155385 7001_ $$0P:(DE-2719)2810712$$aDanek, Adrian$$b5$$udzne
000155385 7001_ $$aBeyer, Leonie$$b6
000155385 7001_ $$aNitschmann, Alexander$$b7
000155385 7001_ $$aKern, Maike$$b8
000155385 7001_ $$aBiechele, Gloria$$b9
000155385 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris Stephan$$b10$$udzne
000155385 7001_ $$aHäckert, Jan$$b11
000155385 7001_ $$0P:(DE-2719)2813308$$aHöllerhage, Matthias$$b12
000155385 7001_ $$aStephens, Andrew W$$b13
000155385 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b14
000155385 7001_ $$0P:(DE-2719)2812285$$aEimeren, Thilo$$b15
000155385 7001_ $$aVillemagne, Victor L$$b16
000155385 7001_ $$aSchildan, Andreas$$b17
000155385 7001_ $$aBarthel, Henryk$$b18
000155385 7001_ $$aPatt, Marianne$$b19
000155385 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b20
000155385 7001_ $$0P:(DE-HGF)0$$aTauopathies, German Imaging Initiative for$$b21$$eCollaboration Author
000155385 7001_ $$aBartenstein, Peter$$b22
000155385 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b23
000155385 7001_ $$0P:(DE-2719)2202037$$aHaass, Christian$$b24
000155385 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b25
000155385 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b26$$eLast author
000155385 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28624$$gp. mds.28624$$n9$$p2104 - 2115$$tMovement disorders$$v36$$x1531-8257$$y2021
000155385 8564_ $$uhttps://pub.dzne.de/record/155385/files/DZNE-2021-00625.pdf$$yOpenAccess
000155385 8564_ $$uhttps://pub.dzne.de/record/155385/files/DZNE-2021-00625.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155385 909CO $$ooai:pub.dzne.de:155385$$popenaire$$pdnbdelivery$$pdriver$$pVDB$$popen_access
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000882$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000155385 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810712$$aExternal Institute$$b5$$kExtern
000155385 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001808$$aExternal Institute$$b10$$kExtern
000155385 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2813308$$aExternal Institute$$b12$$kExtern
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812285$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000155385 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b20$$kExtern
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2202037$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b25$$kDZNE
000155385 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b26$$kDZNE
000155385 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155385 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000155385 9130_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000155385 9141_ $$y2021
000155385 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000155385 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155385 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000155385 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000155385 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155385 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000155385 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000155385 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000155385 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x0
000155385 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger 1$$lTranslational Neurodegeneration$$x1
000155385 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x2
000155385 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x3
000155385 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x4
000155385 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x5
000155385 980__ $$ajournal
000155385 980__ $$aVDB
000155385 980__ $$aI:(DE-2719)1111016
000155385 980__ $$aI:(DE-2719)1110002
000155385 980__ $$aI:(DE-2719)1111015
000155385 980__ $$aI:(DE-2719)1011202
000155385 980__ $$aI:(DE-2719)5000006
000155385 980__ $$aI:(DE-2719)1110007
000155385 980__ $$aUNRESTRICTED
000155385 9801_ $$aFullTexts